Eterna Therapeutics IncNASDAQ:ERNANASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE2.1500
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots2.0500/ 4
- Ask / Lots2.3300/ 35
- Open / Previous Close2.0500 / 2.1500
- Day Range
- 52 Week Range
- Volume3,912
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ERNA |
|---|---|---|
| 09:34 ET | 200 | 2.05 |
| 09:41 ET | 201 | 2.1 |
| 01:12 ET | 100 | 2.15 |
| 01:46 ET | 100 | 2.15 |
| 02:08 ET | 100 | 2.15 |
| 02:31 ET | 1039 | 2.15 |
| 03:41 ET | 100 | 2.15 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Eterna Therapeutics Inc | 11.6M | -0.5x | --- |
Connect Biopharma Holdings Ltd | 83.7M | 0.0x | --- |
Hepion Pharmaceuticals Inc | 11.6M | -0.2x | --- |
Inhibitor Therapeutics Inc | 11.8M | -3.9x | --- |
Monopar Therapeutics Inc | 11.8M | -1.0x | --- |
Aslan Pharmaceuticals Ltd | 12.2M | -0.2x | --- |
Company Information
Eterna Therapeutics Inc. is a life science company committed to realizing the potential of messenger ribonucleic acid (RNA) (mRNA) cell engineering to provide patients with transformational new medicines. The Company has in-licensed a portfolio of over 100 patents covering key mRNA cell engineering technologies, including technologies for mRNA cell reprogramming, mRNA gene editing, the NoveSlice and UltraSlice gene-editing proteins, and the ToRNAdo mRNA delivery system (collectively mRNA technology platform). Its mRNA gene-editing technology is designed to delete, insert and repair deoxyribonucleic acid (DNA) sequences in living cells, which may be useful for correcting disease-causing mutations, making cells resistant to infection and degenerative disease, modulating the expression of immunoregulatory proteins to enable the generation of durable allogeneic cell therapies, and engineering immune cells to more effectively fight cancer.
Contact Information
- Headquarters
- 1035 Cambridge Street, Suite 18ACAMBRIDGE, MA, United States 02141
- Phone
- 212-582-1199
- Fax
- 302-655-5049
Executives
- Chairman of the Board
- James Bristol
- President, Chief Executive Officer
- Sanjeev Luther
- Chief Financial Officer
- Sandra Gurrola
- Independent Director
- Peter Cicala
- Independent Director
- Dorothy Clarke
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $11.6M |
|---|---|
Revenue (TTM) | $68.0K |
Shares Outstanding | 5.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 4.29 |
EPS | $-4.08 |
Book Value | $0.41 |
P/E Ratio | -0.5x |
Price/Sales (TTM) | 171.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -31,080.88% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
